Table 2.

Risk of high-grade dysplasia or malignancy according to dilatation of the main pancreatic duct in IPMN

Reference	Study design	Number of patients	MPD dilatation	Patients with either high-grade dysplasia or malignancy (%)
Ogawa et al 127 2008	Retrospective	61	≥6 mm	91
Shin et al 128 2010	Retrospective	204	≥6 mm	30
Abdeljawad et al 95 2014	Retrospective	52	≥8 mm	56
Hackert et al 94 2015	Retrospective	320	≥5 mm	59
Seo et al 93 2016	Retrospective	158	≥5 mm	49

MPD, main pancreatic duct.